Who are VOQUEZNA® Triple Pak®'s main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/voquezna-triple-pak.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

VOQUEZNA® Triple Pak® — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

VOQUEZNA® Triple Pak® (VOQUEZNA® Triple Pak®) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Potassium-competitive acid blocker (PCAB) combination therapy. Area: Gastroenterology / Infectious Disease.

marketed Potassium-competitive acid blocker (PCAB) combination therapy H+ K+-ATPase (vonoprazan component); bacterial cell wall and protein synthesis (amoxicillin and clarithromycin) Gastroenterology / Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

VOQUEZNA® Triple Pak® (VOQUEZNA® Triple Pak®) — University of Miami. VOQUEZNA Triple Pak is a combination therapy containing vonoprazan (a potassium-competitive acid blocker) plus amoxicillin and clarithromycin that eradicates Helicobacter pylori by suppressing gastric acid and delivering dual antibiotics.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
VOQUEZNA® Triple Pak® TARGET	VOQUEZNA® Triple Pak®	University of Miami	marketed	Potassium-competitive acid blocker (PCAB) combination therapy	H+ K+-ATPase (vonoprazan component); bacterial cell wall and protein synthesis (amoxicillin and clarithromycin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Potassium-competitive acid blocker (PCAB) combination therapy class)

University of Miami · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). VOQUEZNA® Triple Pak® — Competitive Intelligence Brief. https://druglandscape.com/ci/voquezna-triple-pak. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing